首頁 > 市場調查報告書 > 醫療設備

藥物遞輸設備呼吸器

市場調查報告書

商品編碼

1830958

霧化器市場

Nebulizers Market

出版日期: 2025年09月24日 | 出版商:

The Insight Partners | 英文 150 Pages | 商品交期: 1-5個工作天內

價格

簡介目錄

2024 年霧化器市值為 8.6646 億美元，預計到 2031 年將達到 13.1557 億美元；預計 2025-2031 年期間的複合年成長率將達到 6.2%。市場洞察與分析師觀點：對霧化器市場的預測是基於從各種二手和一手研究來源收集的見解。

霧化器是一種用於管理藥物的設備，有助於緩解喘息等呼吸系統疾病，並幫助清除肺部分泌物。它將液體藥物轉化為細小的霧滴，透過面罩或吸嘴吸入，使藥物直接進入肺部。與其他吸入器不同，霧化器使用由牆壁插座供電的空氣壓縮機。

影響霧化器市場成長的促進因素和限制因素近年來，由於技術進步和產品小型化，家用醫療保健設備日益普及。這一趨勢推動了家用醫療保健設備的普及。此外，老齡人口的增加、慢性呼吸系統疾病 (CRD) 的高發病率以及不斷上漲的醫療成本，促使人們越來越傾向於選擇家庭護理治療。由於緊湊、便攜、方便用戶使用的家用霧化器，以及旨在降低噪音和增強功能的技術創新，家庭醫療保健為昂貴的住院治療提供了一種經濟高效的替代方案。此外，多種藥物均可霧化給藥，包括長效BETA2-激動劑 (LABA)、長效毒蕈鹼受體拮抗劑、類固醇、抗生素和黏液溶解劑。近期推出的家用產品包括：

2023 年 1 月，Synergy Life Science, Inc. 推出了 Nebi，這是一款由電池供電的緊湊型霧化器，適用於各種應用。 2021 年 7 月，HCmed Innovations 的 Pulmogine 振動網狀霧化器獲得 FDA 批准，這是一款攜帶式、方便用戶使用的設備，非常適合需要吸入療法的患者。 2020 年 6 月，Respira Technologies, Inc. 推出了其 RespiRx 藥物輸送設備平台，這是一款超便攜的手持式振動網狀霧化器 (VMN)，設計用於局部和全身治療各種疾病，包括氣喘和 COPD。這些進步將霧化器的應用範圍從診所和醫院的急性護理環境擴展到家庭護理環境。

然而，一些因素阻礙了霧化器市場的成長，包括社區對氣喘缺乏認知和了解、醫療保健服務有限、醫療系統負擔過重、診斷檢測（例如肺量計）不足、醫護人員培訓不足以及氣喘管理指南未得到落實。這些問題導致氣喘漏診，導致患者使用不適當的藥物治療，臨床療效不佳，最終預計將阻礙市場成長。儘管全球氣喘盛行率不斷上升，但人們明顯不願接受傳統療法，因為許多人更喜歡阿育吠陀和家庭療法。氣喘和慢性阻塞性肺病 (COPD) 的治療指南已發生重大變化，吸入性皮質類固醇 (ICS) 是氣喘的一線治療藥物，可單獨使用或與長效BETA-內醯胺類藥物 (LABA) 聯合使用，而長效毒蕈鹼拮抗劑是 COPD 的一線治療藥物。這些特殊的治療組合導致先進攜帶式霧化器的成本增加。 Pubmed Central 於 2020 年 9 月發表的一項研究評估了靜脈注射甲基潑尼松龍與霧化布地奈德在治療慢性阻塞性肺病急性加重期 (AECOPD) 的實際成本效益，並得出結論：對於中國 AECOPD 患者，霧化布地奈德與靜脈注射甲基潑尼松龍相比並非一種成本效益更高的選擇。因此，缺乏早期診斷以及霧化治療的高昂費用是市場成長的重大障礙。

策略洞察報告細分與範圍：「2031年全球霧化器市場分析」是一項全面的研究，重點關注全球市場動態，以識別關鍵促進因素、未來趨勢和獲利機會，從而幫助精準定位主要收入來源。該報告旨在提供市場概覽，並按類型、應用程式和最終用戶進行詳細細分。霧化器市場報告的範圍包括北美（美國、加拿大和墨西哥）、歐洲（西班牙、英國、德國、法國、義大利和歐洲其他地區）、亞太地區（韓國、中國、印度、日本、澳洲和亞太其他地區）、中東和非洲（南非、沙烏地阿拉伯、阿拉伯聯合大公國和中東和非洲其他地區）以及南美洲和中美洲（巴西、阿根廷和南美洲其他地區）。

細分分析：市場依類型分為噴射霧化器、超音波霧化器和網狀霧化器。噴射霧化器在2022年佔據了最大的市場。預計網狀霧化器在2023-2031年期間的複合年成長率最高。噴射霧化器是一種經濟高效且使用者友好的設備，以氣霧劑形式輸送藥物。它們設計為一次性使用，無需滅菌，並最大限度地降低了污染風險。噴射霧化器通常用於機械通氣。這些霧化器在治療慢性呼吸疾病 (CRD) 方面的各種應用正在推動預測期內噴射霧化器市場的成長。

根據應用，市場分為 COPD、氣喘、囊性纖維化等。預計 2023 年 COPD 領域將佔據霧化器市場的最大佔有率，而氣喘領域預計在 2023-2031 年期間的複合年成長率最高。 COPD 是一種慢性發炎性肺部疾病，會阻礙肺部氣流，症狀包括呼吸困難、咳嗽、產生黏液和喘息。它主要是由長期接觸香煙煙霧等刺激物引起的。 COPD 患者罹患心臟病、肺癌和其他健康問題的風險更高。根據世界衛生組織 (WHO) 的數據，COPD 是全球第三大死因。隨著呼吸系統疾病負擔的增加，對吸入療法的需求也增加。此外，向家庭護理治療的轉變正在促進手持霧化器在治療 COPD 和氣喘的使用。

根據最終用戶，霧化器市場分為醫院和診所、急診中心和家庭護理場所。醫院和診所領域在2023年佔據了最大的市場佔有率，並且由於各種類型的霧化器在醫療領域的普及以及這些設備在醫院環境中的日益普及，預計在2023年至2030年期間將實現最高的複合年成長率。

區域展望：2023年，北美佔據了霧化器市場的最大佔有率，其中美國位居榜首，加拿大緊隨其後，原因是該地區慢性阻塞性肺病 (COPD) 和氣喘的盛行率不斷上升。根據默沙東 (MSD) 診療手冊的一篇文章，約有1600萬人患有慢性阻塞性肺病 (COPD)，這是一種主要的死亡原因，每年在美國奪走超過15萬人的生命。推動北美霧化器市場成長的其他因素包括先進醫療設備的引入、醫療支出的增加以及歐姆龍醫療 (OMRON Healthcare)、BD 和 GE 醫療等主要市場參與者在該地區的存在。

霧化器市場報告範圍產業發展與未來機會：根據公司新聞稿，全球霧化器市場主要參與者採取的幾項措施包括：

2021 年 12 月，西普拉有限公司 (Cipla Limited) 啟動了一項計劃，利用其在整個護理過程中的廣泛影響力以及廣泛的藥物-設備組合和治療方法，提高印度各地農村初級衛生保健中心獲得霧化治療急性哮喘的機會。 2021 年 3 月，PARI Pharma GmbH 推出了其 LAMIRA 霧化器系統，該系統獲准在日本銷售 ARIKAYCE（阿米卡星脂質體吸入混懸液）。該系統採用基於 eFlow 技術的先進氣霧劑輸送技術，並配有一個可容納 8.4 毫升全劑量藥物的定製藥物儲液器。 2021 年 3 月，歐姆龍醫療公司 (OMRON Healthcare, Inc.) 與美國氣喘和過敏基金會 (AAFA) 合作，提供醫療級霧化器，以支持 AAFA 的宣傳和計劃，旨在提高氣喘社區中最脆弱成員的意識。競爭格局與主要公司：霧化器市場報告中介紹的知名公司包括歐姆龍醫療公司 (OMRON Healthcare, Inc.)；荷蘭皇家飛利浦公司 (Koninklijke Philips NV)、PARI GmbH、Vectura Group Ltd、Drive DeVilbiss International、Briggs Healthcare、GF Health Products Inc.、GE Healthcare Healthcare、Axtaner)。這些公司專注於開發新技術、改進現有產品並拓展地理範圍，以滿足日益成長的全球消費者需求。

北美洲
- 美國
- 加拿大
- 墨西哥
歐洲
- 德國
- 法國
- 義大利
- 西班牙
- 英國
- 歐洲其他地區
亞太
- 澳洲
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區
南美洲和中美洲
- 巴西
- 阿根廷
- 南美洲和中美洲其他地區

第 11 章：產業格局

併購
協議、合作、合資企業
新產品發布
擴張和其他策略發展

第 12 章：競爭格局

關鍵參與者的熱圖分析
公司定位與集中度

第 13 章：霧化器市場 - 主要公司簡介

GE Healthcare
Agilent Technologies, Inc.
Koninklijke Philips N.V.
Drive DeVilbiss International
Omron Healthcare, Inc.
Vectura Group Ltd
PARI Medical Holding GmbH
Trudell Medical International
Terumo Corporation
GF Health Products

第 14 章：附錄

簡介目錄

Product Code: TIPTE100001066

The nebulizers market was valued at US$ 866.46 million in 2024 and is projected to reach US$ 1315.57 million by 2031; it is anticipated to achieve a CAGR of 6.2% during 2025-2031.

Market Insights and Analyst View:The forecast for the nebulizers market is based on insights gathered from various secondary and primary research sources.

A nebulizer is a device designed to administer medications that assist in managing respiratory issues such as wheezing and to help clear lung secretions. It transforms liquid medication into fine mist droplets, which are inhaled through a mask or mouthpiece, allowing the medicine to enter the lungs directly. Unlike other inhalers, nebulizers utilize an air compressor powered by electricity from a wall outlet.

Drivers and Restraints Affecting Nebulizers Market Growth

In recent years, home healthcare devices have gained popularity due to technological advancements and product miniaturization. This trend has led to an increased adoption of home healthcare devices. Furthermore, the rising elderly population, the high prevalence of chronic respiratory diseases (CRD), and escalating healthcare costs have contributed to a growing preference for home care treatments. Home healthcare offers a cost-effective alternative to expensive hospital stays, thanks to the availability of compact, portable, and user-friendly nebulizers that are well-suited for home use, along with technological innovations aimed at reducing noise and enhancing functionality. Additionally, a variety of medications are available in nebulized forms, including long-acting beta2-agonists (LABAs), long-acting muscarinic receptor antagonists, steroids, antibiotics, and mucolytics. Recent product launches for home use include:

In January 2023, Synergy Life Science, Inc. introduced Nebi, a compact nebulizer powered by batteries suitable for various applications.In July 2021, HCmed Innovations received FDA approval for the Pulmogine Vibrating Mesh Nebulizer, a portable and user-friendly device ideal for patients needing inhalation therapy.In June 2020, Respira Technologies, Inc. launched its RespiRx drug delivery device platform, an ultra-portable handheld vibrating mesh nebulizer (VMN) designed for local and systemic treatment of various conditions, including asthma and COPD.These advancements have broadened the application of nebulizers from acute care settings in clinics and hospitals to home care environments.

However, several factors hinder the growth of the nebulizers market, including a lack of community awareness and understanding of asthma, limited access to healthcare, overburdened healthcare systems, insufficient diagnostic testing (such as spirometry), inadequate training for healthcare providers, and the non-implementation of asthma management guidelines. These issues contribute to the underdiagnosis of asthma, which can lead to poor clinical outcomes for patients using inappropriate medications for their conditions, ultimately expected to impede market growth. Despite the rising global prevalence of asthma, there is a notable reluctance to accept conventional therapies, as many individuals prefer ayurvedic and homemade remedies. Treatment guidelines for asthma and chronic obstructive pulmonary disease (COPD) have evolved significantly, with inhaled corticosteroids (ICSs) being the first-line treatment for asthma, either alone or in combination with LABAs, while long-acting muscarinic antagonists are the first-line treatment for COPD. Such specific treatment combinations have resulted in increased costs for advanced and portable nebulizers. A study published in September 2020 by Pubmed Central evaluated the cost-effectiveness of intravenous methylprednisolone versus nebulized budesonide for treating acute exacerbations of chronic obstructive pulmonary disease (AECOPD) in a practical setting, concluding that nebulized budesonide is not a cost-effective option compared to intravenous methylprednisolone for AECOPD patients in China. Consequently, the lack of early diagnosis and the high costs associated with nebulizing therapy are significant barriers to market growth.

Strategic Insights

Report Segmentation and Scope:The "Global nebulizers market analysis to 2031" is a comprehensive study focusing on global market dynamics to identify key driving factors, future trends, and lucrative opportunities that will help pinpoint major revenue pockets. The report aims to provide an overview of the market with detailed segmentation by type, application, and end-user. The scope of the nebulizers market report includes North America (the US, Canada, and Mexico), Europe (Spain, the UK, Germany, France, Italy, and the Rest of Europe), Asia Pacific (South Korea, China, India, Japan, Australia, and the Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Segmental Analysis:The market is categorized by type into jet nebulizers, ultrasonic nebulizers, and mesh nebulizers. The jet nebulizers segment accounted for the largest market share in 2022. The Mesh Nebulizers segment is expected to exhibit the highest CAGR during 2023-2031. Jet nebulizers are cost-effective and user-friendly devices that deliver medication in aerosol form. They are designed for single-use, eliminating the need for sterilization and minimizing contamination risks. Jet nebulizers are commonly utilized during mechanical ventilation. The various applications of these nebulizers in treating CRD are driving the growth of the jet nebulizers market during the forecast period.

By application, the market is segmented into COPD, asthma, cystic fibrosis, and others. The COPD segment is projected to hold the largest share of the nebulizer market in 2023, while the asthma segment is expected to grow at the highest CAGR during 2023-2031. COPD is a chronic inflammatory lung disease that obstructs airflow from the lungs, with symptoms including difficulty breathing, coughing, mucus production, and wheezing. It is primarily caused by long-term exposure to irritants such as cigarette smoke. Individuals with COPD are at a higher risk of developing heart disease, lung cancer, and other health issues. According to the World Health Organization (WHO), COPD is the third leading cause of death worldwide. As the burden of respiratory diseases increases, so does the demand for inhalation therapies. Additionally, the shift towards home care treatments is boosting the use of handheld nebulizers for managing COPD and asthma.

Based on end-user, the nebulizers market is divided into hospitals and clinics, emergency centers, and home care settings. The hospitals and clinics segment held the largest market share in 2023 and is anticipated to register the highest CAGR from 2023 to 2030 due to the medical availability of various nebulizer types and the growing adoption of these devices in hospital environments.

Regional Outlook:North America accounted for the largest share of the nebulizer market in 2023, with the US leading this region, followed by Canada, due to the rising prevalence of COPD and asthma among the population. According to an article from Merck Sharp & Dohme (MSD) Manual, approximately 16 million individuals suffer from COPD, which is a leading cause of death, claiming over 150,000 lives annually in the US. Other factors driving the growth of the nebulizers market in North America include the introduction of advanced healthcare equipment, increasing healthcare expenditures, and the presence of major market players such as OMRON Healthcare, BD, and GE Healthcare in the region.

Nebulizers Market Report Scope

Industry Developments and Future Opportunities:According to company press releases, several initiatives undertaken by key players in the global nebulizers market include:

In December 2021, Cipla Limited launched an initiative to enhance access to nebulization therapy for managing acute asthma in rural primary healthcare centers across India, leveraging its extensive presence throughout the care continuum and a wide range of drug-device combinations and treatments.

In March 2021, PARI Pharma GmbH introduced its LAMIRA Nebulizer System, authorized to deliver ARIKAYCE (amikacin liposome inhalation suspension) in Japan. This system utilizes advanced aerosol delivery technology based on eFlow Technology and features a customized medication reservoir capable of holding a full dose of 8.4 ml.

In March 2021, OMRON Healthcare, Inc. collaborated with the Asthma and Allergy Foundation of America (AAFA) to provide medical-grade nebulizers to support AAFA's advocacy and initiatives aimed at raising awareness for the most vulnerable members of the asthma community.

Competitive Landscape and Key Companies:Prominent companies profiled in the nebulizers market report include OMRON Healthcare, Inc.; Koninklijke Philips N.V.; PARI GmbH; Vectura Group Ltd; Drive DeVilbiss International; Briggs Healthcare; GF Health Products, Inc.; GE Healthcare; Agilent Technologies, Inc.; Terumo Corporation; and Trudell Medical International. These companies are focused on developing new technologies, enhancing existing products, and expanding geographically to meet the growing global consumer demand.

1. Introduction

1.1 Scope of the Study
1.2 Market Definition, Assumptions and Limitations
1.3 Market Segmentation

2. Executive Summary

2.1 Key Insights
2.2 Market Attractiveness Analysis

3. Research Methodology

4. Nebulizers Market Landscape

4.1 Overview
4.2 PEST Analysis
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain

5. Nebulizers Market - Key Market Dynamics

5.1 Key Market Drivers
5.2 Key Market Restraints
5.3 Key Market Opportunities
5.4 Future Trends
5.5 Impact Analysis of Drivers and Restraints

6. Nebulizers Market - Global Market Analysis

6.1 Nebulizers - Global Market Overview
6.2 Nebulizers - Global Market and Forecast to 2030

7. Nebulizers Market - Revenue Analysis (USD Million) - By Type, 2020-2030

7.1 Overview
7.2 Jet Nebulizers
7.3 Ultrasonic Nebulizers
7.4 Mesh Nebulizers

8. Nebulizers Market - Revenue Analysis (USD Million) - By Application , 2020-2030

8.1 Overview
8.2 COPD
8.3 Asthma
8.4 Cystic Fibrosis
8.5 Others

9. Nebulizers Market - Revenue Analysis (USD Million) - By End-User, 2020-2030

9.1 Overview
9.2 Hospitals and Clinics
9.3 Emergency Center
9.4 Home Care Setting

10. Nebulizers Market - Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis

10.1 North America
- 10.1.1 North America Nebulizers Market Overview
- 10.1.2 North America Nebulizers Market Revenue and Forecasts to 2030
- 10.1.3 North America Nebulizers Market Revenue and Forecasts and Analysis - By Type
- 10.1.4 North America Nebulizers Market Revenue and Forecasts and Analysis - By Application
- 10.1.5 North America Nebulizers Market Revenue and Forecasts and Analysis - By End-User
- 10.1.6 North America Nebulizers Market Revenue and Forecasts and Analysis - By Countries
  - 10.1.6.1 United States Nebulizers Market
    - 10.1.6.1.1 United States Nebulizers Market, by Type
    - 10.1.6.1.2 United States Nebulizers Market, by Application
    - 10.1.6.1.3 United States Nebulizers Market, by End-User
  - 10.1.6.2 Canada Nebulizers Market
    - 10.1.6.2.1 Canada Nebulizers Market, by Type
    - 10.1.6.2.2 Canada Nebulizers Market, by Application
    - 10.1.6.2.3 Canada Nebulizers Market, by End-User
  - 10.1.6.3 Mexico Nebulizers Market
    - 10.1.6.3.1 Mexico Nebulizers Market, by Type
    - 10.1.6.3.2 Mexico Nebulizers Market, by Application
    - 10.1.6.3.3 Mexico Nebulizers Market, by End-User
10.2 Europe
- 10.2.1 Germany
- 10.2.2 France
- 10.2.3 Italy
- 10.2.4 Spain
- 10.2.5 United Kingdom
- 10.2.6 Rest of Europe
10.3 Asia-Pacific
- 10.3.1 Australia
- 10.3.2 China
- 10.3.3 India
- 10.3.4 Japan
- 10.3.5 South Korea
- 10.3.6 Rest of Asia-Pacific
10.4 Middle East and Africa
- 10.4.1 South Africa
- 10.4.2 Saudi Arabia
- 10.4.3 U.A.E
- 10.4.4 Rest of Middle East and Africa
10.5 South and Central America
- 10.5.1 Brazil
- 10.5.2 Argentina
- 10.5.3 Rest of South and Central America

11. Industry Landscape

11.1 Mergers and Acquisitions
11.2 Agreements, Collaborations, Joint Ventures
11.3 New Product Launches
11.4 Expansions and Other Strategic Developments

12. Competitive Landscape

12.1 Heat Map Analysis by Key Players
12.2 Company Positioning and Concentration

13. Nebulizers Market - Key Company Profiles

13.1 GE Healthcare
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Agilent Technologies, Inc.
13.3 Koninklijke Philips N.V.
13.4 Drive DeVilbiss International
13.5 Omron Healthcare, Inc.
13.6 Vectura Group Ltd
13.7 PARI Medical Holding GmbH
13.8 Trudell Medical International
13.9 Terumo Corporation
13.10 GF Health Products